Citigroup
OBX icon

Citigroup’s Obsidian Therapeutics OBX Stock Holding History

Citigroup’s Portfolio OBX Stock Details OBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.75K Buy
+419
New +$8.18K ﹤0.01% 5331

Other funds holding OBX

Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Revelation Capital Management
Revelation Capital Management Sausalito, California $8.01M AUM 49.3% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Danske Bank
Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Citigroup's OBX Position: Q3 2026 in Review

Citigroup opened a new position in Obsidian Therapeutics (OBX) in Q3 2026: 419 shares worth $5.75K. The stake represents ﹤0.01% of the portfolio and ranks #5331 among its holdings.

8 funds tracked by Wall St. Rank hold OBX as of Q3 2026.

  • Citigroup held 419 shares of Obsidian Therapeutics worth $5.75K as of Q3 2026.
  • Obsidian Therapeutics was a new Citigroup position in Q3 2026.
  • Obsidian Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5331 holding.
  • 8 funds tracked by Wall St. Rank held Obsidian Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.